Correspondence 0001493152-22-036182 from OKYO Pharma Ltd (OKYO) (CIK 0001849296) (OKYO)

OKYO Pharma Ltd (OKYO) (CIK 0001849296)
Date: Dec. 21, 2022 · CIK: 0001849296 · Accession: 0001493152-22-036182

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-268675

Date

Dec. 21, 2022

Author

Chief

Form

CORRESP

Company

OKYO Pharma Ltd (OKYO) (CIK 0001849296)

Letter

OKYO Pharma Ltd.

Martello Court

Admiral Park

St. Peter Court

Guernsey GY1 3HB

December 21, 2022

VIA EDGAR

United States Securities

and Exchange Commission

F Street, N.E.

Washington, D.C. 20549

Attention: Tyler Howes

Re: OKYO Pharma Ltd.

Registration Statement on Form F-1/A

File No. 333-268675

Ladies and Gentlemen:

OKYO Pharma Ltd. (the “Company”) hereby respectfully withdraws its request, dated December 16, 2022, that the effective date of the registration statement referred to above be accelerated so that it will become effective at 5:00 p.m., Eastern Standard Time, on Tuesday, December 20, 2022. The Company intends to submit a revised acceleration request at a later date.

Please notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 if there are any question with respect to this request.

Thank you,

OKYO PHARMA LTD.

By: /s/ Gary S. Jacob

Name:

Gary S. Jacob

Title:

Chief Executive Officer

Show Raw Text

CORRESP
1
filename1.htm

OKYO
Pharma Ltd.

Martello
Court

Admiral
Park

St.
Peter Court

Guernsey
GY1 3HB

December
21, 2022

VIA
EDGAR

United
States Securities

and
Exchange Commission

100
F Street, N.E.

Washington,
D.C. 20549

Attention:
Tyler Howes

    Re:
    OKYO
    Pharma Ltd.

    Registration
    Statement on Form F-1/A

    File
    No. 333-268675

Ladies
and Gentlemen:

OKYO
Pharma Ltd. (the “Company”) hereby respectfully withdraws its request, dated December 16, 2022, that the effective date
of the registration statement referred to above be accelerated so that it will become effective at 5:00 p.m., Eastern Standard Time,
on Tuesday, December 20, 2022. The Company intends to submit a revised acceleration request at a later date.

Please
notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 if there are any question
with respect to this request.

    Thank you,

    OKYO PHARMA LTD.

    By:
    /s/ Gary S. Jacob

    Name:

    Gary
    S. Jacob

    Title:

    Chief
    Executive Officer

SecProbe.io